NO20002590L - Formulations comprising dissolved paroxetine - Google Patents

Formulations comprising dissolved paroxetine

Info

Publication number
NO20002590L
NO20002590L NO20002590A NO20002590A NO20002590L NO 20002590 L NO20002590 L NO 20002590L NO 20002590 A NO20002590 A NO 20002590A NO 20002590 A NO20002590 A NO 20002590A NO 20002590 L NO20002590 L NO 20002590L
Authority
NO
Norway
Prior art keywords
paroxetine
solid
formulations
solutions
dissolved
Prior art date
Application number
NO20002590A
Other languages
Norwegian (no)
Other versions
NO20002590D0 (en
Inventor
Ahmad Ghazawi
Graham Stanley Leonard
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20002590D0 publication Critical patent/NO20002590D0/en
Publication of NO20002590L publication Critical patent/NO20002590L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives farmasøytiske formuleringer av paroxetin, hvor paroxetinet er i løsning i en fast, halvfast eller flytende bærer. Løsningene benyttes til fylling av kapsler, eller selvbærende faste løsninger formes til faste doseringsformer som tabletter eller pellets. Det beskrives også nye flytende formuleringer, hvor et solubiliseringsmiddel benyttes til å solubilisere paroxetin i oljer og/eller lipider, samt fremgangsmåter for å unngå at andre paroxetinformer omdannes til hemihydratet, ved bruk av vannfrie eller hydrofobe bærere eller hjelpestoffer.Pharmaceutical formulations of paroxetine are disclosed, wherein the paroxetine is in solution in a solid, semi-solid or liquid carrier. The solutions are used to fill capsules, or self-supporting solid solutions are formed into solid dosage forms such as tablets or pellets. Also described are new liquid formulations, wherein a solubilizing agent is used to solubilize paroxetine in oils and / or lipids, and methods for preventing other paroxetine informants from being converted to the hemihydrate, using anhydrous or hydrophobic carriers or excipients.

NO20002590A 1997-11-21 2000-05-19 Formulations comprising dissolved paroxetine NO20002590L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9724544.3A GB9724544D0 (en) 1997-11-21 1997-11-21 Novel Formulation
PCT/GB1998/003471 WO1999026625A1 (en) 1997-11-21 1998-11-18 Formulations comprising dissolved paroxetine

Publications (2)

Publication Number Publication Date
NO20002590D0 NO20002590D0 (en) 2000-05-19
NO20002590L true NO20002590L (en) 2000-07-19

Family

ID=10822374

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002590A NO20002590L (en) 1997-11-21 2000-05-19 Formulations comprising dissolved paroxetine

Country Status (24)

Country Link
EP (1) EP1033986A1 (en)
JP (1) JP2001523718A (en)
KR (1) KR20010032320A (en)
CN (1) CN1279608A (en)
AP (1) AP2000001821A0 (en)
AR (1) AR015485A1 (en)
AU (1) AU1168099A (en)
BG (1) BG104527A (en)
BR (1) BR9814220A (en)
CO (1) CO4970832A1 (en)
DZ (1) DZ2658A1 (en)
EA (1) EA200000552A1 (en)
GB (1) GB9724544D0 (en)
HU (1) HUP0100580A3 (en)
IL (1) IL136106A0 (en)
MA (1) MA24704A1 (en)
NO (1) NO20002590L (en)
OA (1) OA11385A (en)
PE (1) PE20000381A1 (en)
PL (1) PL340555A1 (en)
SK (1) SK7342000A3 (en)
TR (1) TR200001423T2 (en)
WO (1) WO1999026625A1 (en)
ZA (1) ZA9810637B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810180D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulation
EP1161241B1 (en) * 1999-03-12 2005-12-07 Aesica Pharmaceuticals Ltd. Stable pharmaceutical application form for paroxetin anhydrate
WO2001002393A1 (en) 1999-07-01 2001-01-11 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
DE19930454A1 (en) * 1999-07-02 2001-01-04 Knoll Ag Solid paroxetine-containing preparations
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
JP2005531495A (en) * 2001-12-21 2005-10-20 シャイア ラボラトリーズ，インコーポレイテッド Oral capsule formulation with high physical stability
SE0200475D0 (en) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral pharmaceutical preparation
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20120322752A1 (en) * 2009-12-08 2012-12-20 Sung Kyun Lee SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN103961333B (en) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 Paroxetine mesylate capsule and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
EA002034B1 (en) * 1997-01-15 2001-12-24 Смитклайн Бичам Плс Paroxetine compositions

Also Published As

Publication number Publication date
PL340555A1 (en) 2001-02-12
IL136106A0 (en) 2001-05-20
AR015485A1 (en) 2001-05-02
MA24704A1 (en) 1999-07-01
ZA9810637B (en) 2000-05-22
BR9814220A (en) 2001-12-26
NO20002590D0 (en) 2000-05-19
WO1999026625A1 (en) 1999-06-03
PE20000381A1 (en) 2000-05-07
CO4970832A1 (en) 2000-11-07
SK7342000A3 (en) 2000-12-11
TR200001423T2 (en) 2000-10-23
KR20010032320A (en) 2001-04-16
EP1033986A1 (en) 2000-09-13
AU1168099A (en) 1999-06-15
OA11385A (en) 2004-01-27
EA200000552A1 (en) 2000-10-30
DZ2658A1 (en) 2003-03-22
AP2000001821A0 (en) 2000-06-30
BG104527A (en) 2001-04-30
CN1279608A (en) 2001-01-10
HUP0100580A3 (en) 2002-05-28
JP2001523718A (en) 2001-11-27
HUP0100580A2 (en) 2002-04-29
GB9724544D0 (en) 1998-01-21

Similar Documents

Publication Publication Date Title
US6383471B1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
NO20002590L (en) Formulations comprising dissolved paroxetine
GB2314508A (en) Diamide-dicarboxylic acid microspheres
BR9714310A (en) Pharmaceutical composition
DE69927963D1 (en) GELABLE PHARMACEUTICAL COMPOSITIONS
NO20002133L (en) Solid state solutions and dispersions of weakly water-soluble drugs
ES2196621T3 (en) ADMINISTRATION SYSTEMS OF PHARMACOS THAT USE LIQUID GLASS STRUCTURES.
CA2168732A1 (en) Gelatin Capsules Containing a Highly Concentrated Acetaminophen Solution
DK0501985T3 (en) Uncoated pharmaceutical reaction tablet
UA74339C2 (en) Dosage form of proton pump inhibitor representing individual matrix-included units and method for its manufacture
IS4329A (en) Tablet unit dosage form containing proton pump blocker
ATE215370T1 (en) SELF-EMULSIFYING FORMULATION CONTAINING LIPOPHILIC COMPOUNDS
DE69940674D1 (en) ORAL ADMINISTRATION OF ADENOSINE ANALOG
FR2635265B1 (en) INTRAVENOUS PHARMACEUTICAL COMPOSITION COMPRISING CYCLOSPORIN AS ACTIVE INGREDIENT AND PROCESS FOR THE PREPARATION THEREOF
KR880701544A (en) Dissolution System for Ionizable Pharmaceutical Formulations
DE58902457D1 (en) RETARDED MEDICAL FORM AND METHOD FOR THE PRODUCTION THEREOF.
ES2029776T1 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING BROMOCRIPTINE WITH HIGH STABILITY.
AR013967A1 (en) A DRUG FORMULATION FOR ORAL ADMINISTRATION OF CONTROLLED PELLET PELLET THAT HAS CONTROLLED RELEASE OF AN ACTIVE COMPOUND THAT IS SELECTED FROM THE ACID 1-CYCLOPROPIL-7- [(S, S) -2,8-DIAZABICICLO [4.3.0] NON- 8-IL] -6-FLUOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-CARBOXILIC QUINOLON OR SALE
RU2000131588A (en) PHARMACEUTICAL COMPOSITION
ATE204163T1 (en) ENCAPSULATED MEDICINAL MEDICINE
NO950134L (en) Formulations for orally administered pharmaceutical agents
FR2799660B1 (en) SUPERCRITICAL FLUID EXTRACTION PROCESS
BR0307913A (en) Use of a composition, pharmaceutical composition for nasal administration, and methods to elicit a therapeutic, prophylactic and / or diagnostic effect in a mammal, to obtain a rapid onset of a therapeutic, prophylactic and / or diagnostic effect of an active substance in a mammal and to improve the bioavailability of a therapeutic, prophylactic and / or diagnostic effect of an active substance in a mammal
Wiseman et al. The distribution, excretion and metabolism of benzquinamide
DE69416034D1 (en) Pharmaceutical preparation for rectal administration of pharmacologically active compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application